Carregant...
Current treatment of atypical hemolytic uremic syndrome
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically,...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4204535/ https://ncbi.nlm.nih.gov/pubmed/25343125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5582/irdr.2014.01001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|